☆ 4.7 Editorial Material

Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease

JOURNAL OF CLINICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Oncology

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

Margret Merino et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Review Oncology

US FDA Drug Approvals for Breast Cancer: A Decade in Review

Shaily Arora et al.

Summary: The treatment of patients with breast cancer has been greatly influenced by the approval of various drugs and indications in the past decade. This article summarizes the FDA approvals of 30 treatments for breast cancer from 2010 to 2020, including trial design, results, and regulatory considerations. The majority of approvals were for metastatic breast cancer, with a smaller number for early breast cancer. These approvals were primarily based on progression-free survival, overall survival, or objective response rate, and also involved other review initiatives and designations.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Oncology

US FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Shaily Arora et al.

Summary: There has been significant progress in the treatment of gynecologic cancers over the past decade. This article summarizes the FDA approvals for gynecologic cancer treatments from 2010 to 2020, totaling 17 new indications. Six of these indications received accelerated approval, while 11 received regular approval. The approval decisions were supported by primary efficacy endpoints and showed a favorable benefit-risk profile. The article also discusses the current FDA thinking on drug development opportunities and regulatory initiatives.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Editorial Material Oncology

Introducing Clinical Trial Updates

Kathy D. Miller et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint

Nicholas C. Richardson et al.

LANCET ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics

Bishal Gyawali et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

Joseph C. Del Paggio et al.

Summary: The study indicates that contemporary oncology RCTs mainly measure putative surrogate endpoints and are predominantly funded by the pharmaceutical industry. The increase in the involvement of medical writers is notable. The oncology community needs to evaluate whether study endpoints and target effect sizes truly benefit patients.

JAMA ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Multiplicity Considerations in Clinical Trials

Alex Dmitrienko et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Meeting Abstract Oncology

Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) plus capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy

Ander Urruticoechea et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

N. C. Turner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

Ander Urruticoechea et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Editorial Material Oncology

Combining drugs and extending treatment - a PFS end point is not sufficient

Bishal Gyawali et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, Research & Experimental

Sample size adjustment designs with time-to-event outcomes: A caution

Boris Freidlin et al.

CLINICAL TRIALS (2017)

Add to Collection

Article Oncology

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri et al.

LANCET ONCOLOGY (2016)

Add to Collection

Article Oncology

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

Nicholas C. Turner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Fotios Loupakis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

James Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Editorial Material Oncology

Progression-Free Survival: Meaningful or Simply Measurable?

Christopher M. Booth et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Letter Oncology

Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies

Marc Buyse et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

Edward L. Korn et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Pharmacology & Pharmacy

Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials

H. M. James Hung et al.

JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2007)

Add to Collection

Article Oncology

Preliminary data release for randomized clinical trials of noninferiority: A new proposal

EL Korn et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

Add to Collection

Article Mathematical & Computational Biology

Increasing the sample size when the unblinded interim result is promising

YHJ Chen et al.

STATISTICS IN MEDICINE (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.